Review of phase 2 and 3 trials for novel metabolic medications, including dual and triple agonists, and their potential place in future treatment algorithms.
Review of phase 2 and 3 trials for novel metabolic medications, including dual and triple agonists, and their potential place in future treatment algorithms.
